TITLE

LETTER FROM THE EDITOR

AUTHOR(S)
Lichtenstein, Gary R.
PUB. DATE
January 2013
SOURCE
Gastroenterology & Hepatology;Jan2013, Vol. 9 Issue 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
An introduction is presented in which the editor discusses various articles within the issue on topics including burdens of diverticular disease, and office visits of Crohn's disease patients, and regurgitation of gastroesophageal reflux disease.
ACCESSION #
86415276

 

Related Articles

  • Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Travis, S. P. // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 3, p113 

    A review of the article "Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)," by S. P. Travis and colleagues, which appeared in the periodical "Gut" in 2012 is presented.

  • Elective colectomy for severe ulcerative colitis may reduce mortality more than medical therapy. Naidu, Harini; Farraye, Francis A.; Noronha, Ansu // Evidence Based Medicine;Feb2016, Vol. 21 Issue 1, p29 

    The article reflects on a research related to benefits of using elective colectomy for severe ulcerative colitis to reduce mortality as compared to medical therapy. Topics discussed include challenges faced for management of patients with moderate to severe ulcerative colitis (UC), results...

  • Telemanagement for Inflammatory Bowel Disease. Cross Jr., Raymond K. // Gastroenterology & Hepatology;Apr2014, Vol. 10 Issue 4, p255 

    An interview with physician Raymond K. Cross Jr. is presented. He discusses about how telemedicine can be used in the management of inflammatory bowel disease (IMD) and its impact on office-based practice. He explains about the Home Automated Telemanagement (HAT) system, an example of...

  • Quantification of autofluorescence imaging can accurately and objectively assess the severity of ulcerative colitis. Moriichi, Kentaro; Fujiya, Mikihiro; Ijiri, Masami; Tanaka, Kazuyuki; Sakatani, Aki; Dokoshi, Tatsuya; Fujibayashi, Shugo; Ando, Katsuyoshi; Nomura, Yoshiki; Ueno, Nobuhiro; Kashima, Shin; Gotoh, Takuma; Sasajima, Junpei; Inaba, Yuhei; Ito, Takahiro; Tanabe, Hiroki; Saitoh, Yusuke; Kohgo, Yutaka // International Journal of Colorectal Disease;Dec2015, Vol. 30 Issue 12, p1639 

    Background and aims: No endoscopic examination has been able to evaluate severity of ulcerative colitis (UC) by quantification. This prospective study investigated the efficacy of quantifying autofluorescence imaging (AFI) to assess the severity of UC, which captures the fluorescence emitted...

  • Prolonged-Release Mesalazine: A Review of its Therapeutic Potential in Ulcerative Colitis and Crohn's Disease. Clemett, D.; Markham, A. // Drugs;Apr2000, Vol. 59 Issue 4, p929 

    Prolonged-release mesalazine (Pentasa) consists of ethylcellulose-coated microgranules from which mesalazine (known in the US as mesalamine) is released in the small and large intestine in a diffusion-dependent manner. Dose-dependent improvements in clinical and endoscopic parameters have been...

  • PHARMA: CLINIC ROUNDUP.  // BioWorld Today;1/9/2014, Vol. 25 Issue 6, p12 

    The article offers information on Phase III trials of vedolizumab drug from Takeda Pharmaceutical Co. Ltd. for the treatment of Crohn's disease and ulcerative colitis.

  • Research drug shows promise in IBD.  // New Zealand Doctor;9/11/2013, p42 

    The article presents a research study, funded by Takeda Pharmaceuticals, suggests that an investigational antibody named vedolizumab has potential as a new treatment alternative for Crohn's disease (CD), ulcerative colitis and inflammatory bowel diseases.

  • Group puts Crohn's and colitis on agenda. McMillan, Virginia // New Zealand Doctor;9/8/2010, p20 

    The article reports that the advocacy organization Crohn's and Colitis New Zealand wants the establishment of a national strategy for the management of ulcerative colitis and Crohn's disease.

  • sulfasalazine.  // Royal Society of Medicine: Medicines;2002, p514 

    The article presents information on sulfasalazine, an aminosalicylate which combines within the one chemical a sulphonamide constituent and an aminosalicylate component. It can be used to treat Crohn's disease and to induce and maintain remission of the symptoms of ulcerative colitis. It is also...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics